We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A coalition of unions and patient advocacy groups has urged the Federal Trade Commission to strengthen its requirements for AbbVie and Allergan’s planned $63 billion merger. Read More
The Attorneys General of a dozen states and the U.S. Chamber of Commerce have urged a federal appeals court to dissolve the novel “negotiating class” in the multidistrict opioid litigation, arguing that Judge Dan Polster of the U.S. District Court for the Northern District of Ohio lacked the legal authority to create it. Read More
A federal judge in Massachusetts ruled that seven former Insys Therapeutics executives must pay nearly $57 million in restitution for their role in the company’s scheme to boost prescriptions of its sublingual fentanyl spray Subsys. Read More
Sen. Chuck Grassley (R-Iowa) said he expects his drug pricing bill S. 2543 to pass in the Senate by May 20, just two days before the deadline to renew expiring healthcare programs. Read More
FDA Commissioner Stephen Hahn said the agency is taking a “forward-leaning approach” to identify supply chain shortages caused by the coronavirus outbreak and isn’t waiting around for drugmakers to report them. Read More
“Perhaps no investigation better illustrates our prosecutors’ resolve than our ongoing investigation into the generic pharmaceutical industry,” said DOJ Deputy Assistant Attorney General Richard Powers. Read More
A federal appeals court in Ohio stayed an order requiring pharmacies to submit 14 years of nationwide opioid dispensing data in the state’s ongoing multi-district opioid litigation, limiting the scope to just the state of Ohio. Read More
CBER unveiled its guidance agenda for the 2020, including planned draft guidances on gene therapy for neurodegenerative diseases, CAR-T cell therapies and genome editing. Read More